Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 trial of TXL in treatment-naïve patients with chronic hepatitis B (both HBeAg and HeAg)

Next Previous
X
Search
Trial Profile

A Phase 3 trial of TXL in treatment-naïve patients with chronic hepatitis B (both HBeAg and HeAg)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir exalidex (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Sponsors Hepion Pharmaceuticals

    • Most Recent Events

    • 16 Feb 2018 New trial record
    • 12 Feb 2018 According to a ContraVir Pharmaceuticals media release, the company the U.S. Food and Drug Administration (FDA) has agreed to allow the company to utilize the 505(b)(2) Regulatory Pathway to streamline the development and registration of TXL for the treatment of Chronic Hepatitis B. US FDA also agreed on the major elements of design of this trial including duration of treatment, clinical endpoints, comparator and number of patients needed for NDA submission.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top